Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ligand Pharmaceuticals (LGND) Income from Continuing Operations (2016 - 2025)

Ligand Pharmaceuticals' Income from Continuing Operations history spans 16 years, with the latest figure at 44784000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations rose 244.06% year-over-year to 44784000.0; the TTM value through Dec 2025 reached 124453000.0, up 3186.63%, while the annual FY2025 figure was 124453000.0, 3186.63% up from the prior year.
  • Income from Continuing Operations for Q4 2025 was 44784000.0 at Ligand Pharmaceuticals, down from 117273000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 117273000.0 in Q3 2025 and bottomed at 51911000.0 in Q2 2024.
  • The 5-year median for Income from Continuing Operations is 11122000.0 (2022), against an average of 12268700.0.
  • The largest annual shift saw Income from Continuing Operations crashed 2366.86% in 2024 before it surged 1735.15% in 2025.
  • A 5-year view of Income from Continuing Operations shows it stood at 13799000.0 in 2021, then crashed by 205.33% to 14534000.0 in 2022, then surged by 225.14% to 18188000.0 in 2023, then plummeted by 270.93% to 31088000.0 in 2024, then skyrocketed by 244.06% to 44784000.0 in 2025.
  • Per Business Quant, the three most recent readings for LGND's Income from Continuing Operations are 44784000.0 (Q4 2025), 117273000.0 (Q3 2025), and 4847000.0 (Q2 2025).